Intravenous Triple Therapy in the Treatment of Helicobacter Pylori Infection and Related Complications Caused by Active Peptic Ulcer Disease

• Status: Recruiting
• Trial end date: 2021-06-15
• Target enrollment: 0
• Participant gender: All

Summary

Helicobacter pylori infection causes active peptic ulcer disease and related complications like bleeding and pyloric obstruction. Usually, clinicians tended to treat Helicobacter pylori infection after active peptic ulcer disease and related complicaitons getting healed, which spent time and money. This study is designed to evaluate the efficacy and safety of intravenous administration of metronidazole, levofloxacin and esomeprazole triple therapy in the treatment of Helicobacter pylori infection combined with peptic ulcer disease related complications.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Shanghai Jiao Tong University School of Medicine
• Treatments: Esomeprazole; Levofloxacin; Metronidazole; Ofloxacin

Criteria

Inclusion Criteria:

• Male or female aged between 18 and 75 years old

• Without previous Helicobacter pylori treatment

• Diagnosed with active peptic ulcer disease and related complications like bleeding and pyloric obstruction by endoscopy examination

• Ability and willingness to participate in the study and to sign and give informed consent

• Positive for Helicobacter pylori IgM antibody

Exclusion Criteria:

• With previous gastric surgery

• Major systemic diseases

• Pregnancy or lactation

• Allergy to any of the study drugs

• Decline to participate in the study